Related Experiment Videos
Economic impact of mechanical cardiac assistance
1patrese@aol.com
Insights
Mechanical cardiac assistance offers a viable alternative to heart transplantation, with potential annual program expenditures ranging from $5.4 to $24 billion. This economic outlook necessitates careful consideration for public policy and disease management strategies.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Medical Technology Assessment
Background:
- Limited economic analysis exists for mechanical cardiac assistance compared to heart transplantation.
- Coronary artery disease and congestive heart failure incur substantial annual costs exceeding $65 billion in the US.
- Diverse treatment options necessitate comparative economic evaluations.
Purpose of the Study:
- To estimate the economic implications of mechanical cardiac assistance from procedural and program perspectives.
- To provide policymakers with credible estimates of total program expenditures for mechanical cardiac assistance.
- To compare the economic impact of mechanical cardiac assistance with existing treatments like heart transplantation and end-stage renal disease treatment.
Main Methods:
- Program-level expenditure estimation for mechanical cardiac assistance.
- Comparison of estimated costs with current expenditures for heart transplantation and end-stage renal disease treatment.
Main Results:
- US program expenditures for heart transplantation are estimated between $352 and $700 million annually.
- Total direct annual program expenditures for mechanical cardiac assistance could range from $5.4 billion to $24 billion.
- The economic scale of mechanical cardiac assistance is comparable to or exceeds that of end-stage renal disease treatment ($9.8 billion in 1996).
Conclusions:
- Mechanical cardiac assistance presents a significant economic consideration for public policy.
- The economic viability of mechanical cardiac assistance warrants further investigation and debate.
- Understanding the cost-effectiveness of mechanical cardiac assistance is crucial for future healthcare planning.
Abstract:
In contrast to heart transplantation, little effort has been made to estimate the economic implications of mechanical cardiac assistance from either a procedure- or a program-level perspective. With annual direct and indirect expenditures for the treatment of coronary artery disease and congestive heart failure now exceeding $65 billion in the United States, and the treatment options available for these diseases becoming increasingly diverse, it is important that we begin to better understand how expenditures for various treatment options compare. From a disease management perspective, it is also essential that policymakers have credible estimates of total program expenditures. At this time, program expenditures for heart transplantation in the United States are somewhere between $352 and $700 million. Given the availability of viable long-term mechanical cardiac assistance and the current need for cardiac replacement, total direct annual program expenditures could be as low as $5.4 billion or as high as $24 billion, depending on the expenses associated with device implantation and maintenance. By contrast, in 1996 the United States spent $9.8 billion on the treatment of end-stage renal disease. Clearly, the economics are such that viable mechanical cardiac assistance will likely engender considerable public policy debate.